Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Jan 20

PMID 36661675

Authors

Hao Xiang Chen

Ching-Chan Lin

Che-Hung Lin

Chi-Rei Yang

Affiliations

Soon will be listed here.

Abstract

Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting with anal bleeding and urethra obstruction who responded dramatically to combination therapy of durvalumab and cisplatin-based chemotherapy. The patient had HPV-positive penile squamous cell carcinoma, cT3N3M0, with concomitant anus squamous cell carcinoma. After 2 months of the combination treatment, almost all bulky inguinal lymph nodes shrank, and the main tumor of the anus and penis responded completely. A durable response was seen 16 months after initiating the combination therapy. This case report highlights the potential role of the combination of immunotherapy and chemotherapy in patients with advanced penile cancer. The promising results of this combination resulted in the conversion of unresectable disease to a potentially curable disease.

Citing Articles

Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.

Khalid F, Bodla Z, Gaddameedi S, Macasaet R, Yagnik K, Niaz Z Curr Oncol. 2025; 32(2).

PMID: 39996908 PMC: 11854063. DOI: 10.3390/curroncol32020108.

References

Ottenhof S, Djajadiningrat R, De Jong J, Thygesen H, Horenblas S, Jordanova E . Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. J Urol. 2016; 197(3 Pt 1):690-697. DOI: 10.1016/j.juro.2016.09.088. View

Chahoud J, Skelton 4th W, Spiess P, Walko C, Dhillon J, Gage K . Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab. Front Oncol. 2021; 10:615298. PMC: 7793656. DOI: 10.3389/fonc.2020.615298. View

Colombo N, Dubot C, Lorusso D, Caceres M, Hasegawa K, Shapira-Frommer R . Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021; 385(20):1856-1867. DOI: 10.1056/NEJMoa2112435. View

Trafalis D, Alifieris C, Kalantzis A, Verigos K, Vergadis C, Sauvage S . Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma. J Immunother. 2018; 41(6):300-305. DOI: 10.1097/CJI.0000000000000221. View

McGregor B, Campbell M, Xie W, Farah S, Bilen M, Schmidt A . Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2020; 127(6):840-849. DOI: 10.1002/cncr.33328. View

Djajadiningrat R, Graafland N, van Werkhoven E, Meinhardt W, Bex A, van der Poel H . Contemporary management of regional nodes in penile cancer-improvement of survival?. J Urol. 2013; 191(1):68-73. DOI: 10.1016/j.juro.2013.07.088. View

Pettaway C, Pagliaro L, Theodore C, Haas G . Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology. 2010; 76(2 Suppl 1):S58-65. DOI: 10.1016/j.urology.2010.03.082. View

Yang Y, Qu S, Li J, Hu C, Xu M, Li W . Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021; 22(8):1162-1174. DOI: 10.1016/S1470-2045(21)00302-8. View

Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsague X . Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012; 12:30. PMC: 3293758. DOI: 10.1186/1471-2407-12-30. View

10.

Gao W, Song L, Yang J, Song N, Wu X, Song N . Risk factors and negative consequences of patient's delay for penile carcinoma. World J Surg Oncol. 2016; 14:124. PMC: 4848776. DOI: 10.1186/s12957-016-0863-z. View

11.

Klempner S, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali S . Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2019; 25(1):e147-e159. PMC: 6964127. DOI: 10.1634/theoncologist.2019-0244. View

12.

Backes D, Kurman R, Pimenta J, Smith J . Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2008; 20(4):449-57. DOI: 10.1007/s10552-008-9276-9. View

13.

Subbiah V, Solit D, Chan T, Kurzrock R . The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020; 31(9):1115-1118. DOI: 10.1016/j.annonc.2020.07.002. View

14.

Udager A, Liu T, Skala S, Magers M, McDaniel A, Spratt D . Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016; 27(9):1706-12. PMC: 4999561. DOI: 10.1093/annonc/mdw216. View

15.

Skeppner E, Andersson S, Johansson J, Windahl T . Initial symptoms and delay in patients with penile carcinoma. Scand J Urol Nephrol. 2012; 46(5):319-25. DOI: 10.3109/00365599.2012.677473. View

16.

Bermejo C, Busby J, Spiess P, Heller L, Pagliaro L, Pettaway C . Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007; 177(4):1335-8. DOI: 10.1016/j.juro.2006.11.038. View

17.

Di Lorenzo G, Buonerba C, Federico P, Perdona S, Aieta M, Rescigno P . Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012; 110(11 Pt B):E661-6. DOI: 10.1111/j.1464-410X.2012.11453.x. View

18.

De Bacco M, Carvalhal G, MacGregor B, Marcal J, Wagner M, Sonpavde G . PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region. Clin Genitourin Cancer. 2020; 18(3):e254-e259. DOI: 10.1016/j.clgc.2019.10.014. View

19.

Dou W, Xu J, Liu J, Li X . Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report. Asian J Surg. 2022; 45(3):968-969. DOI: 10.1016/j.asjsur.2021.12.048. View

20.

Mai H, Chen Q, Chen D, Hu C, Yang K, Wen J . Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021; 27(9):1536-1543. DOI: 10.1038/s41591-021-01444-0. View